A Phase I, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of hCBE-11, a Humanized Monoclonal Antibody, in Subjects With Advanced Solid Tumors.

Trial Profile

A Phase I, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of hCBE-11, a Humanized Monoclonal Antibody, in Subjects With Advanced Solid Tumors.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 02 Jun 2015

At a glance

  • Drugs Monoclonal antibody CBE11 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Biogen
  • Most Recent Events

    • 25 Apr 2013 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
    • 13 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top